Últimas noticias sobre Talphera (NASDAQ:TLPH) Bolsa

Talphera

AcelRx Pharmaceuticals

Talphera Inc. is a pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. Its portfolio consists of nafamostat product candidates and pre-filled syringe product candidates.

Talphera Inc

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p><strong>Talphera</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/tlph-stock-quote/"><strong>TLPH</strong></a></span>) just reported results for the second quarter of 2024.</p><ul><li>Talphera reported earnings per share of -15 cents. This was above the analyst estimate for EPS of -23 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div><p>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><p>The post <a href="https://investorplace.com/earning-results/2024/08/tlph-stock-earnings-talphera-for-q2-of-2024/">TLPH Stock Earnings: Talphera Beats EPS for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

TLPH Stock Earnings: Talphera Beats EPS for Q2 2024

Analyst Ed Arce of H.C. Wainwright maintained a Buy rating on Talphera (TLPH – Research Report), with a price target of $6.00. Ed Arce has given hi...

Buy Rating Affirmed for Talphera Amid Strategic Advancements in NEPHRO CRRT Study

Maxim Group analyst Naz Rahman has reiterated their bullish stance on TLPH stock, giving a Buy rating yesterday. Naz Rahman has given his Buy ratin...

Bullish Outlook on Talphera's Niyad: Phase 3 Trial Advancements and Market Potential Justify Buy Rating

Here are the major earnings after the close today

AcelRx Pharmaceuticals GAAP EPS of -$0.13 beats by $0.07

"Our NEPHRO CRRT study has gained momentum, with activated study sites now screening patients and two additional sites to begin screening in the fo...

Talphera reports Q3 EPS (13c) vs. (8c) last year

Talphera, Inc. (TLPH) Q3 2024 Earnings Call Transcript

Analyst Ed Arce from H.C. Wainwright maintained a Buy rating on Talphera (TLPH – Research Report) and keeping the price target at $6.00. Ed Arce ha...

Optimistic Buy Rating for Talphera Driven by Promising NEPHRO CRRT Study Progress and Niyad's Potential

Maxim Group analyst Naz Rahman has reiterated their bullish stance on TLPH stock, giving a Buy rating on November 14. Naz Rahman has given his Buy ...

Talphera's Promising Prospects: Buy Rating Affirmed Amidst Strategic Advancements in Anticoagulant Development

Talphera (TLPH) announced that following a meeting with the FDA, the agency has agreed to review a Prior Approval Supplement requesting a reduction...

Talphera reaches agreement with FDA in Nephro CRRT study

ADAP

AEMD

AGRO

AOIFF

AYTU

BDORY

BNGO

BOXL

BRFS

CAPR

CSCO

DADA

DGII

DRRX

ECOR

GLAD

GOEV

GRYP

HROW

KLIC

NLCP

OMER

OTRK

PVCT

SMSI

SONO

SPRU

TLPH

TTEK

VXRT

Press Releases

Talphera Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Talphera to Host Second Quarter 2024 Financial Results and Corporate Update Call and Webcast on Wednesday, August 14, 2024

Earnings

Talphera Announces Second Quarter 2024 Financial Results and Provides Corporate Update

Talphera Announces First Patient Enrolled in the Registrational Trial Evaluating Nafamostat for Anticoagulation of the Extracorporeal Circuit

Talphera to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

Talphera to Participate in Fireside Chat at the 2024 Maxim Healthcare Virtual Summit

Talphera to Host Third Quarter 2024 Financial Results and Corporate Update Call and Webcast on Wednesday, November 13, 2024

Talphera Announces Third Quarter 2024 Financial Results and Provides Corporate Update

Ascentage Pharma Appoints Ms. Marina S. Bozilenko and Dr. Debra Yu as Independent Non-Executive Directors

Talphera Announces Agreement with the FDA for Prior Approval Supplement Review to Reduce the Number of Patients in the NEPHRO CRRT Study

Comments

Talphera

Noticias

Últimas noticias sobre Talphera (NASDAQ:TLPH) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL